Walter J. Urba

Research interests

Publications

• Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

  Journal of Clinical Oncology · 2022 · 10.1200/jco.22.01763

• Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

  New England Journal of Medicine · 2022 · 10.1056/nejmoa2119662

• Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

  Cancer Cell · 2020 · 10.1016/j.ccell.2020.08.005

• Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

  Journal for ImmunoTherapy of Cancer · 2019 · 10.1186/s40425-019-0645-6

• Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

  Cell · 2017 · https://doi.org/10.1016/j.cell.2017.09.028

• Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

  Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-2677

• Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-16-1272

• Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma

  JAMA Oncology · 2015 · 10.1001/jamaoncol.2015.1184

• The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

  Nature Reviews Clinical Oncology · 2013 · 10.1038/nrclinonc.2013.153

• OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

  Cancer Research · 2013 · 10.1158/0008-5472.can-12-4174

• Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

  Annals of the New York Academy of Sciences · 2013 · 10.1111/nyas.12180

• Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses

  Science Translational Medicine · 2012 · 10.1126/scitranslmed.3003649

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

• Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.16.1927

• Efficient Cross-presentation Depends on Autophagy in Tumor Cells

  Cancer Research · 2008 · 10.1158/0008-5472.can-08-0161

• Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2937

• Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

  Cancer · 2007 · 10.1002/cncr.23086

• A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

  Journal of Immunotherapy · 2006 · 10.1097/01.cji.0000211341.88835.ae

• Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2005.03.206

• Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.02.014

• Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

  The Journal of Immunology · 2000 · 10.4049/jimmunol.164.4.2160

• Hodgkin's Disease

  New England Journal of Medicine · 1992 · 10.1056/nejm199203053261006

• Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.

  Journal of Clinical Oncology · 1992 · 10.1200/jco.1992.10.2.210

• Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

  Cancer · 1990 · 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5

• Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

  New England Journal of Medicine · 1988 · 10.1056/nejm198806023182201

Current projects

No projects listed.